Codexis Announces Appointment of H. Stewart Parker to Board of Directors
December 20 2022 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced the appointment of H. Stewart Parker to its Board
of Directors.
“Stewart’s deep expertise in gene therapy and demonstrated track
record of executive leadership within the biopharmaceutical
industry make her a compelling addition as we seek to continue to
strengthen the diversity of our Board with a breadth of
professional experience, educational background, and viewpoints,”
said Byron Dorgan, Chair of the Board of Codexis. “In particular,
her experience advising publicly traded pharmaceutical and genomic
therapy companies will be valuable as we continue focusing efforts
on programs where we have the greatest potential to create
significant value over the next few years.”
“I am excited to leverage my insights in support of Codexis’
impressive portfolio of assets and exceptional enzyme engineering
capabilities,” said Ms. Parker. “I look forward to working closely
with the talented team in place as we focus on high potential
development programs for long-term growth.”
Ms. Parker previously served as the Chief Executive Officer,
strategic advisor, and a member of the board of directors of the
Infectious Disease Research Institute (IDRI), a nonprofit research
organization focused on the development of products for the
diagnosis, prevention, and treatment of neglected diseases. Prior
to IDRI, Ms. Parker managed the formation of Targeted Genetics
Corporation as a wholly owned subsidiary of Immunex Corporation,
and served as its President and Chief Executive Officer and as a
Director from its spinout from Immunex Corporation. She has also
served in various capacities at Immunex Corporation, most recently
as Vice President, Corporate Development. Since 2014, Ms. Parker
has served on the Board of Directors of IMPEL Pharmaceuticals Inc.,
a publicly traded pharmaceutical company and Sangamo Therapeutics,
Inc., a publicly traded genomic therapies company. Ms. Parker also
currently serves on the Board of Directors of private gene therapy
company StrideBio, Inc. Previously, Ms. Parker served on the board
of directors of publicly traded pharmaceutical companies Achieve
Life Sciences, Inc., and Armata Pharmaceuticals, Inc. (formerly C3J
Therapeutics, Inc.), as well as on the Board of Directors and the
Executive Committee of BIO, the primary trade organization for the
biotechnology industry, and as a Director of Neose Technologies,
Inc. Ms. Parker obtained a B.A. in Slavic Language and Literature
and an M.B.A. in Finance and International Business from the
University of Washington.
About Codexis
Codexis is a leading enzyme engineering company leveraging its
proprietary CodeEvolver® platform to discover and develop
novel, high performance enzymes and biotherapeutics. Codexis
enzymes have applications in the sustainable manufacturing of small
molecule pharmaceuticals and mRNA therapeutics; in the creation of
the next generation of life science tools; and as gene therapies
and oral enzyme therapies. The Company’s unique enzymes drive
improvements such as higher yields, reduced energy usage and waste
generation, improved return on capital in manufacturing, improved
sensitivity in genomic and diagnostic applications, and more
efficacious therapeutics. For more information,
visit www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Codexis, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements regarding the Company’s programs having the potential to
create significant value over the next few years. You should not
place undue reliance on these forward-looking statements because
they involve known and unknown risks, uncertainties and other
factors that are, in some cases, beyond Codexis’ control and that
could materially affect actual results. Additional information
about factors that could materially affect actual results can be
found in Codexis’ Annual Report on Form 10-K filed with the
Securities and Exchange Commission (“SEC”) on February 28, 2022 and
in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on
November 4, 2022, including under the caption “Risk Factors,” and
in Codexis’ other periodic reports filed with the SEC. Codexis
expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Relations Contact:
Argot PartnersBrendan Strong/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024